Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Post date: 2026-02-05 03:26:31
Views: 0
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.